Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

474
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
474
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

156
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
156
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

275
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
275
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

50
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
50
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

39
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
39
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

32
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
32

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Joint impact of the number of comorbidities and the COVID-19 pandemic on the concordance of antibiotic prescriptions with clinical guidelines, in the community.

BMC infectious diseases·2026
Same author

Estimating Nutrient Composition of Packaged Foods Using Natural Language Processing and Optimization Modeling.

Current developments in nutrition·2026
Same author

Initial Cardiovascular Disease Risk Assessment in Nonclinical Settings: Framingham-Simplified Model Predictive Performance in a Canadian Cohort.

CJC open·2026
Same author

[Polypharmacie et déprescription en milieu rural: étude qualitative auprès de personnes aînées et de personnes proches aidantes au Québec].

Canadian journal on aging = La revue canadienne du vieillissement·2026
Same author

2024/25 end-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada.

Vaccine·2026
Same author

QMAP: a benchmark for standardized evaluation of antimicrobial peptide MIC and hemolytic activity regression.

Scientific reports·2026

Related Experiment Video

Updated: Oct 27, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.9K

Exploring polypharmacy with artificial intelligence: data analysis protocol.

Caroline Sirois1,2,3, Richard Khoury4, Audrey Durand4

  • 1Faculty of Pharmacy, Université Laval, Quebec, QC, Canada. caroline.sirois@pha.ulaval.ca.

BMC Medical Informatics and Decision Making
|July 21, 2021
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) will analyze medication use in older adults to improve polypharmacy quality. This approach addresses public health concerns by identifying safe and effective medication patterns for chronic disease patients in Quebec.

Keywords:
Artificial intelligenceEthicsIndicatorsMedicationsPolypharmacySocial acceptability

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.4K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.0K

Related Experiment Videos

Last Updated: Oct 27, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.9K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.4K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.0K

Area of Science:

  • Gerontology
  • Public Health
  • Artificial Intelligence in Medicine

Background:

  • Polypharmacy is prevalent in older adults, posing a significant public health challenge due to potential adverse health outcomes.
  • Traditional statistical methods struggle to identify genuine associations between complex medication regimens and health outcomes.
  • This project addresses the need for advanced analytical approaches to assess polypharmacy quality in elderly populations with chronic conditions.

Purpose of the Study:

  • To leverage artificial intelligence (AI) to determine the quality of polypharmacy among older adults with chronic diseases in Quebec, Canada.
  • To develop explainable AI (XAI) algorithms for identifying medication use patterns correlated with health events, considering temporal and spatial data aspects.
  • To translate AI-identified patterns into actionable polypharmacy indicators for public health surveillance and clinical practice, while ensuring ethical considerations and social acceptability.

Main Methods:

  • Utilizing the Quebec Integrated Chronic Disease Surveillance System (QICDSS) dataset, encompassing 20 years of prescribed medication, diagnostic codes, procedures, and sociodemographic data.
  • Developing AI algorithms to detect frequent medication use patterns and their correlation with health events, incorporating principles of explainable AI (XAI).
  • Establishing health and law/ethics research axes to translate AI findings into public health indicators and assess their social acceptability, non-discrimination, and equity.

Main Results:

  • The AI research axis will generate algorithms capable of identifying complex medication use patterns.
  • The Health research axis will produce novel polypharmacy indicators for surveillance and clinical use.
  • The Law&Ethics research axis will ensure the developed tools are socially acceptable and equitable, without exacerbating health disparities.

Conclusions:

  • This multidisciplinary project will provide a deeper understanding of polypharmacy issues in older adults using AI.
  • The developed AI tools and indicators aim to improve the quality of care and public health surveillance for polypharmacy.
  • Results will be disseminated to stakeholders to inform evidence-based decision-making, ensuring data confidentiality.